My passion to unravel the mysteries of human biology resulted in expertise on three main levels: (1) antitumor immunotherapy with focus on lung cancer and melanoma, (2) applications with lentiviral vectors such as cell line modifications but also vaccination and (3) development of threedimensional tumor immunology models to disclose fundamental keys of tumor resistance to immunotherapy.
Cleo Goyvaerts (°Bonheiden, 29/10/1986) obtained her Bachelor in Veterinary Sciences in 2007, however decided to switch to Biochemistry and Biotechnology, for which she obtained her Master degree in 2010 (UGent). Over the years she developed a passion for oncology, immunology and virology, so when she found out that the lab of Molecular and Cellular Therapy (LMCT) at the VUB had an excellent track record in the development of antitumor immune therapeutics, she was determined to start her FWO-funded PhD project there. During her PhD she broadened her view, knowledge and network in the fields of lentiviral vector based therapeutic vaccination, single domain antibodies, myeloid cells and the tumor microenvironment. Since 2015, Cleo works as a postdoctoral fellow at the LMCT where she focusses on the tumor microenvironment of skin- and lung cancer to enhance currently available (immuno-)therapeutics. Finally, she gained know-how regarding 3D tumor modelling and in vitro killing assays during a one-year lasting postdoctoral training program in the laboratories of Profs. Brian Brown, Miriam Merad and Hélène Salmon at the Tisch Cancer Institute, Mount Sinai Icahn School of Medicine, New York.
As a passionate and hopeful scientist, she’s eager to continue her contribution to the scientific cancer-combating community via collection, analysis and spread of captivating knowledge.